- Home
- PMX vs IMAB Comparison
PMX vs IMAB Comparison
Compare PMX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- IMAB
- Stock Information
- Founded
- PMX 2002
- IMAB 2014
- Country
- PMX United States
- IMAB United States
- Employees
- PMX N/A
- IMAB N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PMX Finance
- IMAB Health Care
- Exchange
- PMX Nasdaq
- IMAB Nasdaq
- Market Cap
- PMX 233.7M
- IMAB 200.9M
- IPO Year
- PMX N/A
- IMAB 2020
- Fundamental
- Price
- PMX $6.73
- IMAB $2.13
- Analyst Decision
- PMX
- IMAB Strong Buy
- Analyst Count
- PMX 0
- IMAB 3
- Target Price
- PMX N/A
- IMAB $6.33
- AVG Volume (30 Days)
- PMX 101.5K
- IMAB 589.5K
- Earning Date
- PMX 01-01-0001
- IMAB 05-15-2025
- Dividend Yield
- PMX 5.28%
- IMAB N/A
- EPS Growth
- PMX N/A
- IMAB N/A
- EPS
- PMX N/A
- IMAB N/A
- Revenue
- PMX N/A
- IMAB N/A
- Revenue This Year
- PMX N/A
- IMAB N/A
- Revenue Next Year
- PMX N/A
- IMAB N/A
- P/E Ratio
- PMX N/A
- IMAB N/A
- Revenue Growth
- PMX N/A
- IMAB N/A
- 52 Week Low
- PMX $6.09
- IMAB $0.60
- 52 Week High
- PMX $8.47
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- PMX 40.67
- IMAB 49.76
- Support Level
- PMX $6.70
- IMAB $2.06
- Resistance Level
- PMX $6.85
- IMAB $2.41
- Average True Range (ATR)
- PMX 0.06
- IMAB 0.33
- MACD
- PMX -0.01
- IMAB -0.07
- Stochastic Oscillator
- PMX 22.22
- IMAB 12.63
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).